For over 20 years, CEDRA Corporation, a division of Worldwide Clinical Trials, has been an industry leader in providing Bioanalytical Sciences and Phase I-IIb Clinical Research Services. Operating as a division of Worldwide Clinical Trials over the past three years, today, CEDRA Corporation announces its new company name, Worldwide Clinical Trials Drug Development Solutions. This unified name adds to the continuity and full-service offerings our companies collectively provide.
“All of our services will remain the same. We chose to change the name of our company to reflect the relationship and corporate identity of the Worldwide Clinical Trials brand”
Worldwide Clinical Trials Drug Development Solutions continues to offer Bioanalytical Sciences and Clinical Research Services, as well as specialized studies to determine the effects of dose, formulation, dosing regimen, drug interactions, genotype, gender and other factors on pharmacokinetics. With continued commitment to provide expert advice on everything from protocol development to regulatory submission, Worldwide Clinical Trials Drug Development Solutions focuses on meticulous care and attention to detail through every stage of the process.
Worldwide Clinical Trials and Worldwide Clinical Trials Drug Development Solutions will use their combined medical and scientific expertise to provide superior service in drug development. With Worldwide Clinical Trials specializing in mid-/late-phase, and Worldwide Clinical Trials Drug Development Solutions specializing in bioanalytical/early-phase clinical trials, the two cover the entire spectrum to meet customer needs on a global level.
"All of our services will remain the same. We chose to change the name of our company to reflect the relationship and corporate identity of the Worldwide Clinical Trials brand," stated Worldwide Clinical Trials Drug Development Solutions CEO, Anthony G. Busa, Jr.
How a new U.S. health study is fixing bias in wearable data research